PCM
KYNB

Prelude Capital Management’s Kyntra Bio KYNB Stock Holding History

Prelude Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-204
Closed -$277K – 1809
2019
Q1 		$277K Buy
204
+196
+2,450% +$266K 0.02% 619
2018
Q4 		$9K Buy
+8
New +$8.99K ﹤0.01% 1387
2016
Q4 		– Sell
-1,540
Closed -$797K – 1620
2016
Q3 		$797K Buy
+1,540
New +$725K 0.08% 241

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's KYNB Position: Q3 2023 in Review

Prelude Capital Management sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 677 shares — an estimated $45.7K sold.

Prelude Capital Management first reported a position in KYNB in Q4 2015 and held it in 14 quarters. The position peaked at $301K in Q2 2021. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Prelude Capital Management reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 677 Kyntra Bio shares in Q3 2023, an estimated $45.7K.
  • Prelude Capital Management first reported a position in Kyntra Bio in Q4 2015 and held it in 14 quarters.
  • Prelude Capital Management's Kyntra Bio position peaked at $301K in Q2 2021.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.